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UNCERTAINTIES
Does tranexamic acid improve outcomes in traumatic
brain injury?
Abda Mahmood doctoral candidate in epidemiology and population health 1, Ian Roberts professor
of epidemiology and population health 1, Haleema Shakur senior lecturer in clinical trials 1, Tim Harris
professor of emergency medicine 2, Antonio Belli professor of trauma neurosurgery 3
1Clinical Trials Unit, London School of Hygiene and Tropical Medicine, University of London, UK; 2Department of Emergency Medicine, Royal London
Hospital, Barts Health NHS Trust, London, UK; 3NIHR Surgical Reconstruction and Microbiology Research Centre, University Hospitals Birmingham
NHS Foundation Trust, Birmingham, UK
Worldwide at least 200 per 100 000 people are killed or admitted
to hospital each year after traumatic brain injury.1 This results
in more than 10 million deaths or hospital admissions.2 In the
UK, around one million people attend emergency departments
every year with a traumatic brain injury.3
Intracranial bleeding is common after traumatic brain injury,
and the larger the bleed the greater the risk of death and
disability.4 5Bleeding continues after hospital admission in 84%
of patients with moderate or severe injuries,6 7 and can continue
for up to 24 hours.8 About one third of patients have laboratory
evidence of abnormal coagulation.9 High levels of fibrin
degradation products are seen within the first three hours.10 Such
patients have a higher risk of intracranial haemorrhage and
mortality.
Tranexamic acid reduces bleeding by inhibiting the enzymatic
breakdown of fibrin blood clots (fig 1⇓).
Tranexamic acid is used routinely in some cases of trauma and
in surgery. For example, it reduces the need for blood transfusion
in surgical patients.11 12 In trauma patients with extracranial
haemorrhage:13
• Tranexamic acid treatment within an hour of injury reduces
the risk of death caused by bleeding by about one third
(5.3% tranexamic acid v 7.7% placebo relative risk 0.68,
95% confidence interval 0.57 to 0.82; P<0.001);
• treatment between one and three hours reduces the risk by
about one fifth (4.8% v 6.1%; 0.79, 0.64 to 0.97; P=0.03);
• there is no apparent benefit after three hours, and
tranexamic acid might even be harmful (4.4% v 3.1%; 1.44,
1.12 to 1.84; P=0.004).14
If tranexamic acid is effective after traumatic brain injury, it
should also be most effective when given soon after injury,
when intracranial bleeding is ongoing.8
The potential for harm also exists however.
• Tranexamic acid may increase the risk of ischaemia and
cerebral thrombosis because it inhibits fibrinolysis.15
Cerebral ischaemia is already a known risk after after
traumatic brain injury, whichworsens neurological outcome
and increases mortality.16 17 For example, raised intracranial
pressure can lead to cerebral hypoperfusion.18-20Thrombotic
disseminated intravascular coagulation might increase the
risk of cerebral microthrombi, which are often seen in the
brains of patients with traumatic brain injury who have
died.21
• Seizures are also a risk because tranexamic acid is known
to cross the blood-brain barrier.22 Although there was no
evidence of any increase in seizures in the CRASH-2 trial
of tranexamic acid in extracranial bleeding, seizure activity
remains a concern because the blood-brain barrier is
impaired after traumatic brain injury.23
What is the evidence of uncertainty?
A 2015 systematic review identified two relevant completed
randomised trials (table 1⇓).24 25We judged that both trials were
at low risk of bias; however, neither was large enough to answer
the question definitively—the confidence intervals were wide
and the P values statistically insignificant. The first trial (n=249)
examined the effect of tranexamic acid in patients with
extracranial bleeding but who also had traumatic brain injury.24
The second trial (n=229) examined the effect of tranexamic acid
in patients with polytrauma and traumatic brain injury, or
isolated traumatic brain injury.25 Both trials recruited patients
who were within eight hours of injury but the numbers were
not large enough to determine the balance of risks and benefits
from tranexamic acid and whether this varies by time to
treatment. Furthermore, the patients in one of the trials had
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What you need to know
• The effectiveness and safety of tranexamic acid in traumatic brain injury is uncertain, although randomised trials are under way to
investigate the problem
• Tranexamic acid could reduce intracranial bleeding but might increase the risk of cerebral thrombosis and ischaemia
• We believe that tranexamic acid should not be used in routine clinical practice unless these trials show benefit
Box 1: Literature search
A 2015 systematic review of randomised trials of antifibrinolytic agents (including tranexamic acid) after acute traumatic injury, searched:
the Cochrane Injuries Group’s specialised register, Cochrane Library, Ovid Medline(R), Ovid Medline(R) In-process and other non-indexed
citations, Ovid Medline(R) Daily and Ovid Medline(R), Embase Classic+Embase (OvidSP), PubMed and clinical trials registries.30
The review authors rated the quality of the evidence according to the GRADE approach and considered: impact of the risk of bias of individual
trials; precision of the pooled estimate; inconsistency or heterogeneity; indirectness of evidence; and impact of selective reporting and
publication bias on effect estimate. Risk of bias was assessed using the Cochrane Collaboration’s “risk of bias” tool.
As the last update was published in May 2015, we reran the search to identify no new completed trials and one new pending trial
(NCT02645552).
extracranial bleeding in addition to intracranial bleeding.24
Because tranexamic acid reduces mortality in extracranial
bleeding (CRASH-2), the mortality reduction seen in this trial
could be from the extracranial injury rather than any effect on
the brain injury itself.
When the two randomised trials are combined in ameta-analysis
(fig 2⇓), there is a statistically significant reduction in
intracranial haemorrhage, but because the confidence intervals
are wide, the quality of this evidence is low.
• Intracranial haemorrhage—relative risk 0.75 (95%
confidence interval 0.58 to 0.98); P=0.03;
• Mortality—relative risk 0.63 (95% confidence interval
0.40 to 0.99); P=0.05.
The effect of tranexamic acid on disability and thrombotic
adverse effects including stroke remains uncertain.
Is ongoing research likely to provide
relevant evidence?
We identified three ongoing randomised trials of tranexamic
acid versus placebo in patients with isolated traumatic brain
injury (table 2⇓). These will evaluate the effect of tranexamic
acid on death, disability, vascular occlusive events, and other
adverse events in traumatic brain injury. The ongoing trials
inform whether tranexamic acid can be given to those with
traumatic brain injury.
In two of the ongoing trials (n=1402) patients are randomised
within two hours of injury in the prehospital setting
(NCT02645552, NCT01990768).
In the largest trial, the CRASH-3 trial (n=13 000), patients will
be randomised in hospital and within eight hours of injury
(NCT01402882).26 The size of this trial should ensure that
tranexamic acid and placebo groups are similar for known and
unknown confounders, such as the concomitant degree of
coagulopathy.27 Therefore, it is unnecessary to standardise
tranexamic acid and placebo groups for clinical management
factors that may influence the extent of bleeding.
The results from the three ongoing trials should provide
clinicians with information about whether the effect of
tranexamic acid varies by time to treatment. Information on the
effect of tranexamic acid administered within one hour, between
one and three hours, and after three hours of injury may be more
useful than the average effect of the treatment. Prespecified
subgroup analyses in the CRASH-3 trial will provide
information about the effect of tranexamic acid by time to
treatment.
A substudy conducted within the CRASH-3 trial will use
computed tomography scans to examine the effect of tranexamic
acid on intracranial bleeding and thrombosis. These scans can
detect traumatic haemorrhage (high attenuation) in the acute
stage of traumatic brain injury. Ischaemic lesions (low
attenuation) are visible on a computed tomography scan done
several hours after injury. This substudy will provide
information on the effect of tranexamic acid on intracranial
haemorrhage and ischaemia and whether this varies by time to
treatment.
Further research
Randomised trials looking at the effect of tranexamic acid in
patients with isolated traumatic brain injury are currently
ongoing. These trials will address the uncertainty of whether
tranexamic acid improves outcomes in patients with traumatic
brain injury. At this stage we do not make recommendations
for further research in this area.
What should we do in light of the
uncertainty?
The authors recommend that patients with isolated traumatic
brain injury should not receive tranexamic acid outside the
context of a randomised trial, and clinicians should consider
enrolling their patients in one of the relevant trials wherever
possible.
Box 3 signposts other aspects of management of traumatic brain
injury.
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Box 3: Guidelines for general management of traumatic brain injury
The National Institute for Health and Care Excellence provides guidance on the assessment and early management of adults and children
with traumatic brain injury.28 The key recommendations are to:
• First treat the greatest threat to life and avoid further harm by assessing Airway, Breathing, and Circulation
• Maintain cervical spine immobilisation until a full risk assessment indicates it is safe to remove the immobilisation device
• Ascribe depressed consciousness level to intoxication only after a major brain injury has been excluded
• Effectively manage pain, because it can lead to a rise in intracranial pressure
• Immediately manage patients who present to the emergency department with a Glasgow coma scale score of less than 15
• Immediately manage patients who return to the emergency department within 48 hours of transfer to the community with any persistent
problem relating to the initial head injury; these patients should be seen by or discussed with a senior clinician experienced in head injuries,
and considered for a computed tomography scan
• Immediately intubate and ventilate patients in a coma (Glasgow coma scale score ≤8), or patients who cannot protect their airway or have
abnormal respirations
• Transfer patients with a Glasgow coma scale score of 8 or less to a neuroscience unit irrespective of the need for neurosurgery
• Perform a computed tomography scan within one hour of injury if patients present with certain risk factors—for example, Glasgow coma
scale score of less than 13 on initial assessment; suspected skull fracture; post-traumatic seizure; focal neurological deficit; more than one
episode of vomiting. Perform a computed tomography scan within eight hours of injury if patients have experienced loss of consciousness
or amnesia since the injury and show certain risk factors (eg, age ≥65, history of bleeding or clotting disorders, dangerous mechanism of
injury). Perform a CT scan within eight hours of injury if patients are receiving warfarin treatment
• Monitor children closely and perform a computed tomography scan within an hour of injury if a relevant risk factor is identified—eg, suspicion
of non-accidental injury, post-traumatic seizure without history of epilepsy
• Provide patients, family members, and carers with information about the nature and severity of the injury, risk factors that mean the patient
should return to the emergency department—eg, loss of consciousness, amnesia for events before or after injury, headaches, vomiting
episodes—details about what to expect during recovery, contact details of community and hospital services and support organisations, on
discharge
The Centers for Disease Control and Prevention and the American College of Emergency Physicians provide guidance on the management
of adults with mild traumatic brain injury.29 The guidelines focus on determining whether patients with known or suspected mild traumatic
brain injury require a computed tomography scan of the brain or may be safely discharged.
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as the European Federation of Road Traffic Victims, and RoadPeace, the UK national charity for road crash victims, advised the investigators
on outcome measures that matter most to patients, such as fatigue. Organisations also represent patients on the trial steering committee
and are involved in the ongoing supervision of the trial.
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Tables
Table 1| Patients with intracranial haemorrhage, cerebral ischaemia, and mortality outcomes in two randomised trials of tranexamic acid
(TXA) in patients with traumatic brain injury. Values are numbers (percentages) unless stated otherwise
Yutthakasemsunt et al 201325CRASH-2 intracranial bleeding substudy 201224Outcome
Relative risk (95% CI)PlaceboTXARelative risk (95% CI)PlaceboTXA
0.65 (0.40 to 1.05)32 (27)21 (18)0.80 (0.59 to 1.09)56 (44)44 (36)Intracranial haemorrhage
-3 (3)0 -0.51 (0.20 to 1.32)12 (9)6 (5)Focal ischaemic lesion/stroke
0.69 (0.35 to 1.39)17 (14)12 (10)0.60 (0.33 to 1.11)24 (18)14 (11)Deaths
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Table 2| Ongoing randomised trials of tranexamic acid use for traumatic brain injury
Secondary outcomesPrimary outcomeComparisonInterventionNo of
arms
Proposed sample
size
StatusTrial typeTrial
Vascular occlusive
events (myocardial
infarction, stroke,
pulmonary embolism,
and deep vein
thrombosis)
Neurological
outcome (based
on extended
Glasgow outcome
scale score) at six
months post-injury
Placebo
(sodium
chloride,
0.9%)
Arm 1: 1 g intravenous
bolus of tranexamic acid
over 10 minutes
Arm 2: placebo intravenous
bolus over 10 minutes
2400 patients with
moderate to severe
traumatic brain injury
(Glasgow coma
scale score ≤12)
Pending
recruitment
Double
blind,
randomised
trial
Prehospital
tranexamic acid
use for moderate
and severe
traumatic brain
injury
(NCT02645552)
Volume of intracranial
haemorrhage, disability
rating scale score, 28
day survival,
neurosurgery,
ventilator-free days,
Neurological
outcome (based
on extended
Glasgow outcome
scale score) at six
months after injury
Placebo
(sodium
chloride,
0.9%)
Arm 1: 1 g intravenous
bolus of tranexamic acid
followed by 1 g intravenous
infusion of tranexamic acid
over eight hours.
Arm 2: 2 g intravenous
bolus of tranexamic acid
31002 patients with
moderate to severe
traumatic brain injury
(Glasgow coma
scale score ≤12)
Currently
recruiting
Double
blind,
randomised
trial
Prehospital
tranexamic acid
use for traumatic
brain injury
(NCT01990768)
seizures, cerebral
ischaemia, vascularfollowed by placebo infused
over eight hours.
Arm 3: placebo intravenous
bolus followed by placebo
infused over eight hours*
occlusive events,
alterations in fibrinolysis
Vascular occlusive
events, disability (based
on disability rating scale
and patient oriented
outcome measures),
seizures, neurosurgery,
Death in hospital
within 28 days of
randomisation
Placebo
(sodium
chloride,
0.9%)
Arm 1: 1 g of intravenous
bolus of tranexamic acid
over 10 minutes followed by
1 g intravenous infusion of
tranexamic acid over eight
hours.
Arm 2: placebo intravenous
bolus followed by placebo
infused over eight hours
213 000 patients with
major traumatic brain
injury (Glasgow
coma scale score
≤12 or intracranial
bleeding on
computed
tomography scan)
Currently
recruiting
Double
blind,
randomised
trial
Clinical
Randomisation of
an Antifibrinolytic
in Significant
Haemorrhage
(CRASH-3)
(NCT01402882) days in intensive care,
other adverse events
*Intravenous bolus administered in prehospital setting, and maintenance infusion initiated on arrival at hospital.
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Figures
Fig 1 A Normal fibrinolysis. B: Fibrinolysis inhibited by tranexamic acid. Plasmin binds to fibrin via lysine binding sites and
then splits fibrin into fibrin degradation products. Tranexamic acid is a molecular analogue of lysine that inhibits fibrinolysis
by reducing the binding of plasmin to fibrin
Fig 2 Meta-analysis of effect of tranexamic acid (TXA) versus placebo on intracranial bleeding in patients with traumatic
brain injury
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